Overview of Topelia

Topelia Aust Limited is dedicated to developing and commercialising its proprietary Antiviral Triple Therapy (ATT), known as TPL101. Topelia's strategic approach leverages the safety profiles of ivermectin and doxycycline, combined with zinc, to offer a promising antiviral therapy. This methodology not only expedites development but also addresses the ongoing need for effective treatments against COVID-19 and other viral infections. By utilising these approved components, Topelia accelerates the development process, reducing both timelines and associated costs, while minimising the inherent risks of new drug development.

Following consultations with regulatory authorities, Topelia has completed two Phase 1 clinical trials and recently initiated a Phase 3 trial for TPL101. The company plans to submit an application for Therapeutic Goods Administration (TGA) approval in 2025. 

Beyond COVID-19, TPL101's mechanism of action targets proteins conserved across various viruses, suggesting potential efficacy against other respiratory infections, including Avian influenza and diseases caused by the Flaviviridae family, such as Dengue, Zika, and Yellow Fever.